Adjuvant Chemotherapy Trial for High-Risk Rectal Cancer Patients

Strategic Insights -

Researchers at the Erasmus Medical Center have initiated a Phase 3 clinical trial to investigate the efficacy of adjuvant chemotherapy in preventing disease recurrence in patients with high-risk rectal cancer who have detectable circulating tumor DNA (ctDNA) after surgery. The trial, led by principal investigator Cornelis Verhoef, MD, PhD, aims to recruit 103 participants from the USA. This study is a collaborative effort between Erasmus Medical Center, Prospectief Landelijk CRC Cohort (PLCRC), and the Dutch Colorectal Cancer Group (DCCG).

Key Takeaways:

  • The REACT study is a Phase 3 clinical trial designed to evaluate the effectiveness of adjuvant chemotherapy in preventing disease recurrence in high-risk rectal cancer patients with detectable ctDNA after surgery.
  • The trial's primary objective is to determine whether adjuvant chemotherapy improves disease-free survival in this patient population.
  • Participants will be randomly assigned to either receive adjuvant chemotherapy (4 cycles of CAPOX/6 cycles of FOLFOX) within 12 weeks after surgery or not receive chemotherapy.
  • The trial is a collaboration between Erasmus Medical Center, PLCRC, and DCCG, emphasizing the importance of interdisciplinary research in addressing cancer treatment challenges.
  • Cornelis Verhoef, MD, PhD, serves as the principal investigator for this study, underscoring his expertise in the field of cancer treatment.
  • The trial's focus on high-risk rectal cancer patients with detectable ctDNA highlights the significance of personalized medicine and biomarker research in cancer treatment.

Statistics:

  • The trial aims to enroll 103 participants from the USA.
  • The study will randomly assign participants to either receive adjuvant chemotherapy or not receive chemotherapy.
  • The trial is designed to investigate the efficacy of adjuvant chemotherapy in improving disease-free survival in high-risk rectal cancer patients.
  • The study's recruitment period has not commenced, and the trial is currently not open for recruiting participants.

Sources:

  • ClinicalTrials.gov
  • Erasmus Medical Center